2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.Peer-Reviewed Original ResearchConceptsPrimary peritoneal cancerPeritoneal cancerPredictive biomarkersDay 1Taxane-resistant ovarian cancerPhase II trialM2 days 1Bevacizumab 10Evaluable patientsPrior bevacizumabWeekly ixabepiloneII trialPrimary endpointSecondary endpointsRefractory statusTUBB3 expressionPrior receiptSubgroup analysisClinical trialsOvarian cancerIxabepilonePFSCancerBevacizumabPatients
2004
Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index
O'Hanlan KA, Huang GS, Lopez L, Garnier AC. Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index. Gynecologic Oncology 2004, 93: 137-143. PMID: 15047227, DOI: 10.1016/j.ygyno.2003.12.020.Peer-Reviewed Original ResearchMeSH KeywordsAdnexa UteriAdultAgedAged, 80 and overBody Mass IndexFallopian Tube NeoplasmsFemaleHumansHysterectomyLaparoscopyMiddle AgedOvarian NeoplasmsRetrospective StudiesConceptsTotal laparoscopic hysterectomyBody mass indexAdnexal pathologyUrological injuriesLaparoscopic hysterectomyBMI groupsMass indexOvarian carcinomaExact testRecurrent breast cancerMean surgery durationMean complication rateFisher's exact testObstructive adhesionsEarly complicationsHospital stayStage IAChart abstractionComplication rateNodal yieldBlood lossOvarian pathologyMucinous cystadenomaPelvic massMean age